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Malaria StudyAbstract
Background: Chloroquine (CQ) was the main malaria therapy worldwide from the 1940s until the 1990s. Following
the emergence of CQ-resistant Plasmodium falciparum, most African countries discontinued the use of CQ, and now
promote artemisinin-based combination therapy as the first-line treatment. This change was generally initiated
during the last decade in West and Central Africa. The aim of this study is to describe the changes in CQ
susceptibility in this African region, using travellers returning from this region as a sentinel system.
Methods: The study was conducted by the Malaria National Reference Centre, France. The database collated the
pfcrtK76T molecular marker for CQ susceptibility and the in vitro response to CQ of parasites from travellers’ isolates
returning from Senegal, Mali, Ivory Coast or Cameroon. As a proxy of drug pressure, data regarding CQ intake in
febrile children were collated for the study period. Logistic regression models were used to detect trends in the
proportions of CQ resistant isolates.
Results: A total of 2874 parasite isolates were genotyped between 2000–2011. The prevalence of the pfcrt76T
mutant genotype significantly decreased for Senegal (from 78% to 47%), Ivory Coast (from 63% to 37%), Cameroon
(from 90% to 59%) and remained stable for Mali. The geometric mean of the 50% inhibitory concentration (IC50) of
CQ in vitro susceptibility and the proportion of resistant isolates (defining resistance as an IC50 value > 100 nM)
significantly decreased for Senegal (from 86 nM (59%) to 39 nM (25%)), Mali (from 84 nM (50%) to 51 nM (31%)),
Ivory Coast (from 75 nM (59%) to 29 nM (16%)) and Cameroon (from 181 nM (75%) to 51 nM (37%)). Both analyses
(molecular and in vitro susceptibility) were performed for the 2004–2011 period, after the four countries had
officially discontinued CQ and showed an accelerated decline of the resistant isolates for the four countries.
Meanwhile, CQ use among children significantly deceased in this region (fixed effects slope = −0.3, p < 10-3).
Conclusions: An increase in CQ susceptibility following official withdrawal of the drug was observed in travellers
returning from West and Central African countries. The same trends were observed for molecular and in vitro
analysis between 2004-2011and they correlated to the decrease of the drug pressure.
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Chloroquine (CQ) was the main malaria therapy world-
wide between the 1940s and the 1990s, due to its effect-
iveness, safety, low cost and antipyretic properties.
Resistance to CQ emerged in different locations in the late
1950s, first in Southeast Asia (Thai-Cambodian border)
and in South America (Colombia and Venezuela) [1-3].
Resistance spread relatively rapidly and was detected in
East Africa (Kenya and Tanzania) in the late 1970s, prob-
ably as a consequence of an importation of resistant
strains from Asia [4,5]. It was first reported in West Africa
in the early 1980s [6-8]. Despite evidence of a relatively
high prevalence of CQ resistance in Africa for more than
two decades, this single drug remained the first-line treat-
ment of uncomplicated Plasmodium falciparum malaria
recommended in most sub-Saharan African countries
until the early 2000s. Consequently, a significant increase
of clinical malaria morbidity and mortality in children
under five years was attributable to CQ resistance from
the 1980s to the 1990s [9-11]. Malawi was the first African
country to change its national drug policies from CQ to
sulphadoxine-pyrimethamine (SP) in 1993. In time, all
malaria-endemic countries on the African continent
discontinued the routine use of CQ against P. falciparum.
The change of policy to artemisinin-based combination
therapy (ACT) as first-line treatment for uncomplicated
P. falciparum malaria occurred in all endemic countries
between 2000 and 2009.
The frequency of pfcrtK76T mutation in P. falciparum
has been associated with clinical CQ resistance and
represents a good indicator of the parasite’s intrinsic re-
sistance to CQ [12,13]. Since the withdrawal of CQ, previ-
ous studies have documented a decrease in the prevalence
of CQ-resistant parasites. In East Africa, a decrease has
been well described in Malawi after the CQ ban in 1993
and in Kenya after the CQ ban in 1999 [14-16]. A clinical
trial conducted in Malawi in 2005 even confirmed the re-
turn of in vivo CQ efficacy to 99% versus less than 50% be-
fore 1993 [17]. A few studies in West Africa, particularly
in Senegal, have described the same trend for CQ suscep-
tibility after the drug was withdrawn from first-line in
2003 [18,19]. The relationship between drug pressure and
trends in CQ susceptibility has been confirmed in several
countries where information was available [20].
The assessment of parasites imported from malaria en-
demic regions is also a potential tool for monitoring malar-
ial drug resistance; that approach has been tested in this
study. It is assumed that travellers returning to non-
endemic areas with malaria are infected with a wide variety
of Plasmodium strains which partly reflect the parasite
populations in the visited regions. The fact that travellers
are likely to be non-immune with a low risk of re-infection
also facilitates the detection of truly resistant isolates. This
study describes the longitudinal changes in molecular andin vitro correlates of CQ resistance in parasites from
travellers to West and Central Africa, following the with-
drawal of CQ as the recommended treatment.
Methods
Data and samples collection
The study was conducted by the National Reference
Centre for Malaria (CNR), France in collaboration with the
WorldWide Antimalarial Resistance Network (WWARN).
Travellers who returned to France with symptomatic
P. falciparum infections were included in the study. Four
countries, Senegal, Mali, Ivory Coast and Cameroon, had
sufficiently large numbers of returnees for meaningful
comparison. Data sets from 2000 to 2011, for these
countries under consideration, were included in the
study. Cases originated in one of 80 hospitals participat-
ing in the French sentinel network for malaria. An
imported malaria infection was defined by two factors,
positive thin and thick blood smear and a recent travel
history to one of the four chosen countries in the
two months prior to diagnosis, without evidence of au-
tochthonous or transfusion-related transmission. Each
case was prospectively registered in the French national
database after medical records were checked. Basic
demographic and epidemiologic data, clinical and para-
sitological information, treatment, history of travel and
malaria infection were collected systematically. Blood
samples were collected from about half of the French
hospital network, which document anti-malarial drug re-
sistance, for molecular and in vitro analyses. Only
samples with parasitaemia above 0.1% were analysed
in vitro. No informed consent was required for this
study as all following procedures are part of the routine
French national surveillance system of malaria.
Molecular analysis
A total of 2,874 pre-treatment isolates were collected be-
tween 2000–2011. Before 2006, all the samples were sys-
tematically and prospectively analysed by the PCR-RFLP
method to distinguish the pfcrt76K from the pfcrt76T al-
lele related to CQ resistance [19,21]. After 2006, because
of financial constraints, only 30 samples per year and
per country were randomly selected for a retrospective
molecular analysis. DNA was extracted from blood
samples for molecular analysis using the QIAamp DNA
Mini Kit, QiagenW before 2008 and the MagNA Pure LC
DNA Isolation Kit I, Roche after 2008.
In vitro assay
A total of 1,483 fresh venous blood isolates taken before
treatment were centralized and tested for in vitro suscepti-
bility between 2000–2011. Thin blood smears were
examined to determine P. falciparum density and P. fal-
ciparum mono-infection. The batches of plates were
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strain (Africa) and the CQ-resistant W2 reference strain
(Indochina) using the standard 42-hour 3H-hypoxanthine
uptake inhibition method in controlled atmospheric
conditions in the incubator (5% CO2, 10% O2 and
85% N2) [22-24]. In vitro isotopic microtests were
performed, aliquoting 200 μl/well of the suspension of
parasitized erythrocytes into 96-well plates pre-dosed with
anti-malarial drugs. Radioactivity incorporated by the
parasites was measured using a scintillation counter. The
in vitro susceptibility was determined by measuring the
concentration of drug required to inhibit parasite growth
by 50% (50% inhibitory concentration (IC50)) for each of
the isolates [25,26]. The IC50 value was calculated using
the inhibitory sigmoid Emax model, with estimation of the
IC50 through nonlinear regression [27]. Susceptibility
to CQ, desethylamodiaquine, mefloquine and lumefan-
trine were determined, and for CQ, isolates with an IC50
value > 100 nM were defined as resistant [28].
Drug use
CQ usage within the four countries of interest in West
and Central Africa was estimated using the data avail-
able from the demographic health surveys (DHS) and
multiple indicator cluster surveys (MICS) [29,30]. DHS
and MICS are nationally representative household
surveys, which provide the data required for monitoring
and assessing health indicators. They are conducted ap-
proximately every five years, using large sample sizes
(between 5,000 and 30,000 households). Data on the
number of febrile children under five years old that
received CQ in the previous two weeks were extracted
from 88 surveys in 40 African countries, using Measure
DHS and United Nations Children’s Fund (UNICEF)
databases between 2000 and 2011.
Sample size calculation
In order to select eligible countries with enough data per
year for significant molecular analysis, a sample size cal-
culation, using a simple logistic regression model was
used. In the model,
logit Pð Þ ¼ β0 þ β1X;
where P is the prevalence of mutant isolates and X is the
time covariate, the null hypothesis H0: slope (β1) = 0 was
tested for one normally distributed covariate X [31]. The
sample size formula for a two-sample t-test was used:
n ¼ Z1a=2 þ Z1β
 2
P 1 Pð Þ βð Þ2 ;
with a test significance level α = 0.05, a power 1-β = 0.80,
Zu the upper percentile of the standard normal distribu-
tion, the event rate at the mean of X: P = 0.5 and β* theeffect size = 0.405. The total sample size required for
showing a significant increase of 10% of CQ susceptibil-
ity over time was 209 patients for each country (approxi-
mately 20 patients per year for each country).
Statistical analyses
Molecular
Isolates that carried both pfcrtK and pfcrtT alleles were
identified in many isolates, but the proportion of these
mixed isolates proportions was constant over time,
tested with a chi-square test for trend. Therefore, the
prevalence of mutations at the pfcrt76T allele was
calculated as the proportion of mutant isolates (pure +
mixed genotype) out of the total of all isolates (pure mu-
tant + wild-type +mixed genotype). With this approach,
the frequency of mutant alleles in the population of
isolates may be over-estimated and the frequency of
wild-type allele, potentially underestimated. To describe
trends in the prevalence of mutant isolates through time,
a logistic regression model with a logit link function was
fitted to the prevalence data with time as a linear
covariate for each country. Given the probability of mu-
tant isolates, the number of mutant isolates per year was
assumed to be binomially distributed.
The estimated slopes of the logistic regression curve
fitted to the observed mutant allele prevalence and the
95% confidence intervals were presented in logit scale.
The slopes of the changes in prevalence among the
countries were extracted from the model and compared
to assess whether the slopes differed significantly from
null (0) and differed significantly from each other [32].
In vitro
In order to describe the temporal trends of in vitro data,
a generalized linear model (GLM) was fitted with a log
link function to IC50 data throughout the period 2000–
2011 and after 2004:
log IC50ð Þ ¼ α0 þ α1t;
where t is the time covariate. It was tested whether the
slope α1 was significantly different from zero. The geo-
metric means of the IC50 values per year were used to
minimise the effects of outlier values. The threshold
value of IC50 value > 100 nM was used as a definition
of in vitro resistance to CQ [28].
Drug use
The individual patient responses from each DHS or
MICS survey were aggregated to give the weighted num-
ber of positive responses to CQ use. The model was fit-
ted using a mixed effects model for 40 different African
countries to account for heterogeneity across countries.
The probability Pij of CQ use in country i and survey j
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logit pij
  ¼ αþ βtj þ γ i þ λitj;
where α is the fixed effects common intercept, β the fixed
effects common slope for the time variable tj (the year of
the jth survey), yi the intercept random effect at the coun-
try level and λi the slope random effect at the country
level. α + γi represents the country specific log-odds inter-
cept for the ith country and β + λi the country specific
log-odds slope of CQ use against time. By including the
random effects components, the intercept and slope may
differ from country to country. After fitting a model for
CQ use across 40 African countries, results were extracted
to estimate drug usage in Senegal, Mali, Ivory Coast and
Cameroon between 2000 and 2011.
Software
All statistical analyses were performed using Stata ver-
sion 11 for Windows (Stata Corp, College Station, TX,
USA) and R version 2.10.
Results
Travellers’ characteristics
A total of 12,331 travellers infected with P. falciparum
returned to France between 2000 to 2011 from Senegal
(n = 1,970), Mali (n = 2,338), Ivory Coast (n = 4,765), and
Cameroon (n = 3,258), were reported to the National
Malaria Reference Centre, Paris, France (Figure 1). Of
the total cases, the median age of the studied population
was 31 years old, with 79% (n = 8,187) of the travellersFigure 1 Imported malaria infection from West and Central Africa rep
Plasmodium falciparum infections diagnosed in travellers returning to Franc
National Reference Centre for Malaria (CNRpalu), Paris, France, from 2000 toolder than 15 years old. Mainly men were infected (61%,
n = 7,546). The duration of stay was more than one
month for 61% (n = 6,162) of the travellers. The purpose
of travel was to visit friends and relatives (VFR) for 61%
(n = 6,848), living as expatriates/residents for more than
six months for 14% (n = 1,572), tourism for 13% (n =
1,484), business for 5% (n = 543); and, military posting
for 4% (n = 435). Only 38% (n = 4,708) reported taking
prophylaxis during their travel in the endemic country.
Most cases were uncomplicated malaria (95%, n =
11,146) (Table 1). The travellers returning from the four
countries presented similar characteristics.Molecular results
The overall goal was to compare the trends in resistance,
parasite susceptibility to CQ and the relationship of these
values to an estimate of actual drug use in each country.
From 2000 to 2011, the prevalence of the pfcrt76T allele in
parasites from patients returning from Senegal significantly
decreased from 78% to 47% (slope = −0.17, p < 10-3); from
63% to 37% for Ivory Coast (slope = −0.15, p < 10-3); and,
from 90% to 59% for Cameroon (slope = −0.09, p < 10-3)
but no significant decrease of CQ-resistant isolates was
observed for Mali (slope = −0.01, p = 0.72) (Table 2).
By 2004, CQ use had been discontinued in all of these
countries. The same analyses were repeated over the period
2004–2011. The decrease in the prevalence of the pfcrt76T
genotype was significant and faster in all cases than during
the period 2000–2011. In Senegal (slope = −0.18, p < 10-3),
Mali (slope =−0.10, p = 0.03), Ivory Coast (slope = −0.27,orted in the French Malaria Surveillance system. Number of
e from Senegal, Mali, Ivory Coast and Cameroon notified to the
2011.
Table 1 Characteristics of travellers returning from Senegal, Mali, Ivory Coast, Cameroon to France, 2000–2011
Travellers Senegal
(n = 1,993)*
Mali
(n = 2,372)*
Ivory Coast
(n = 4,778 )*
Cameroon
(n =3,272) *
Total
(n = 12,415)
Age (year) (Median [Min-Max]) 30 [0–94] 31 [0–76] 30 [0–83] 33 [0–87] 31 [0–94]
Age class, years n (%)
≤5 78 (4) 118 (6) 349 (9) 185 (7) 730 (7)
5-15 247 (14) 339 (17) 585 (15) 307 (11) 1,478 (14)
>15 1,447 (82) 1,546 (77) 2,995 (76) 2,199 (82) 8,187 (79)
Sex
Male n (%) 1,414 (71) 1,622 (69) 2,764 (58) 1,746 (54) 7,546 (61)
Female n (%) 572 (29) 736 (31) 1,990 (42) 1,512 (46) 4,810 (39)
Chemoprophylaxis
No n (%) 1,113 (56) 1,182 (50) 2,485 (52) 1,993 (61) 6,773 (55)
Yes n (%) 746 (38) 959 (41) 1,955 (41) 1,048 (32) 4,708 (38)
Don’t know n (%) 124 (6) 216 (9) 322 (7) 218 (7) 880 (7)
Duration of stay
≤2 weeks n (%) 218 (13) 152 (8) 457 (12) 439 (16) 1,266 (12)
2-4 weeks n (%) 356 (21) 361 (18) 1,150 (30) 868 (33) 2,735 (27)
1-3 months n (%) 699 (41) 928 (48) 1,221 (32) 679 (25) 3,527 (35)
>3 months n (%) 428 (25) 498 (26) 1,021 (26) 688 (26) 2,635 (26)
Purpose of travel
VFRs n (%) 1,108 (61) 1,520 (71) 2,482 (58) 1,738 (59) 6,848 (61)
Residents or expatriates ≥6 months n (%) 237 (13) 207 (9) 568 (13) 560 (19) 1,572 (14)
Tourism n (%) 322 (18) 251 (12) 514 (12) 397 (13) 1,484 (13)
Business n (%) 71 (4) 90 (4) 212 (5) 170 (6) 543 (5)
Military n (%) 24 (1) 15 (1) 368 (9) 28 (1) 435 (4)
Other n (%) 48 (3) 67 (3) 142 (3) 68 (2) 325 (3)
Severe malaria
No n (%) 1,834 (93) 2,235 (95) 4,513 (95) 3,064 (95) 11,146 (95)
Yes n (%) 136 (7) 123 (5) 225 (5) 177 (5) 661 (5)
No pfcrt76 analyses 594 701 860 719 2874
No In vitro analyses for CQ 305 396 729 513 1483
*Numbers may not add to totals because of missing values.
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lence decreased (Figure 2). When the mixed genotype
isolates were removed from the analyses, the same trends
were observed. To compare these trends with those from
other regions, published data sets of similar molecular data
from Kenya and Malawi, after CQ withdrawal, were
accessed and the logistic regression model fitted to these
data [14,16]. The slopes of the prevalence of pfcrt76T were
strongly negative: Malawi, 1993–2000 (slope = −0.25, p <
10-3) and Kenya, 1999–2006 (slope = −0.20, p = 0.003)
(Figure 2). However, comparison of the slopes showed no
significant differences among the six countries (p = 0.22).
In vitro results
A second way of assessing changes in CQ susceptibility
was to measure the response of isolates in vitro. From
2000 to 2011, the geometric mean of the IC50 of CQ ofthe isolates tested in vitro by the 3H-hypoxanthine up-
take inhibition method decreased significantly in each
country. In Senegal, the value decreased from 86 nM
(95% confidence interval [95% CI], 51–145, 59% resist-
ant) to 38 nM (95% CI, 25–59, 25% resistant); from 84
nM (95% CI, 35–198, 50% resistant) to 51 nM (95% CI,
36–73, 31% CQ resistant) in Mali; from 75 nM (95% CI,
43–130, 59% resistant) to 30 nM (95% CI, 22–40, 16%
resistant) in Ivory Coast and from 181 nM (95% CI, 87–
374, 75% resistant) to 50 nM (95% CI, 36–69, 37% re-
sistant) in Cameroon (Table 2).
Constraining the analyses over the period 2004–2011
resulted in an even faster decrease of in vitro susceptibility
for CQ for the four African countries: Cameroon (slope =
−0.10, p < 10-3), Ivory Coast (slope =−0.12, p < 10-3), Mali
(slope =−0.10, p < 10-3) and Senegal (slope =−0.12, p < 10-3)
(Figure 3A, Table 2).
Table 2 Trends in molecular genotypes and in vitro susceptibility for P. falciparum isolates
Slopes of prevalence in Pfcrt76T
2000-2011 2004-2011
Slope (95% CI) P value Slope (95% CI) P value
Senegal −0.167 [−0.209; -0.125] <10-3 −0.182 [−0.264; -0.102] <10-3
Mali −0.009 [−0.052; 0.034] 0.72 −0.102 [−0.178; -0.027] 0.03
Ivory Coast −0.146 [−0.183; -0.111] <10-3 −0.265 [−0.325; -0.207] <10-3
Cameroon −0.090 [−0.130; -0.050] <10-3 −0.106 [−0.172; -0.041] <10-3
Slopes of IC50 values for CQ
Senegal −0.081 [−0.130; -0.032] <10-3 −0.123 [−0.220; -0.026] <10-3
Mali −0.042 [−0.090; 0.007] 0.02 −0.098 [−0.167; -0.030] <10-3
Ivory Coast −0.057 [−0.093; -0.021] <10-3 −0.120 [−0.177; -0.063] <10-3
Cameroon −0.055 [−0.089; -0.020] <10-3 −0.100 [−0.154; -0.046] <10-3
Slopes of prevalence in Pfcrt76T and slopes of IC50 values from patients returning to France from Senegal, Mali, Ivory Coast, and Cameroon, between 2000–2011
and 2004–2011 (after CQ withdrawal).
Figure 2 Evolution of the prevalence of pfcrt76T isolates after the CQ ban in different African regions. Observed and fitted (by logistic
regression) prevalence of pfcrt76 mutant isolates and 95% Confidence Interval, from travellers returning to France from A) Senegal, B) Mali C)
Ivory Coast, and D) Cameroon, from 2004 to 2011, after that most African countries officially banned the use of CQ. The slopes and their standard
error are displayed for each country. Each spot represents the number of isolates per year for travellers’ data and per study for field studies. The
size of the spot is proportional to the number of isolates. The p-value indicates whether the slope of the predicted line is significantly different
from zero (data from CNRpalu, France). These data are compared with two field studies E) in Malawi and F) Kenya after the CQ ban (1993 for
Malawi and 1999 for Kenya) [14,16].
Gharbi et al. Malaria Journal 2013, 12:35 Page 6 of 11
http://www.malariajournal.com/content/12/1/35
Figure 3 Evolution of in vitro anti-malarial drug response in imported malaria. A generalized linear model is fitted to the in vitro data
A: chloroquine response (IC50), B: desethylamodiaquine response, C: mefloquine response, D: lumefantrine response, for clinical isolates collected
from travellers returning to France from Senegal, Mali, Ivory Coast, and Cameroon, from 2004 to 2011. Slopes, standard errors and the p-value
indicating whether the slope of the predicted line is significantly different from zero are displayed (data from CNRpalu, France). Each spot
represents the geometric mean IC50 per year and the size of the spot is proportional to the number of isolates.
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diaquine, mefloquine and lumefantrine was also examined
as they are components of artemisinin combination ther-
apy currently in use. Moreover, some in vitro studies have
suggested that there is cross-resistance between amo-
diaquine and CQ because of their similar chemical struc-
ture [33]. Mefloquine and lumefantrine belong to the
amino-alcohol class and some in vitro studies have also
suggested an inverse relationship between the responses of
CQ and amino-alcohols [34,35]. The in vitro responses of
isolates for these other drugs were also determined for the
period 2004–2011. The geometric mean of the IC50 values
for desethylamodiaquine (active metabolite of amodia-
quine) showed a significant decline in each of the four
countries (Figure 3B). Susceptibility to mefloquine showed
an increasing trend in Ivory Coast and Cameroon, but the
values were stable in Senegal and Mali (Figure 3C). In con-
trast, the susceptibility in vitro to lumefantrine was stable
in all four countries (Figure 3D).The in vitro and molecular methods are indirect
indicators of parasite resistance to anti-malarial drugs,
but allow efficient longitudinal and temporal surveillance
of any changes. In particular, these approaches have been
used to track the trends in resistance following the
change from CQ to other drugs as recommended first
line therapies [14,16,36]. The actual drug use in a coun-
try is, of course, a key parameter in such changes. To
examine these trends, the drug use data were extracted
from DHS and MICS surveys in the four target coun-
tries, applying a mixed effects model. The percentage
usage of CQ in children with fever in 88 surveys from
40 African countries showed the general decrease in use
from 2000 to 2011 (fixed effects slope = −0.3, p <10-3;
random effects slope = 0.076, p <10-3). The significant
decrease during this period was more specifically
observed in Senegal, from 38% to 2% (slope = −0.33, p <
0.01); from 42% to 13% in Mali (slope = −0.16, p < 0.01);
from 56% to 18% in Ivory Coast (slope = −0.18, p < 0.01);
Gharbi et al. Malaria Journal 2013, 12:35 Page 8 of 11
http://www.malariajournal.com/content/12/1/35and from 49% to 2% in Cameroon (slope = −0.37, p <
0.01), after extracting results from the mixed effects
model.
Using these estimates of trends in CQ use, there was a
positive correlation between CQ use and prevalence of the
pfcrt76T allele in Senegal (r2 = 0.79, p < 0.01) and Ivory
Coast (r2 = 0.74, p < 0.01) but not in Mali (r2 = 0.18, p =
0.57) or Cameroon (r2 = 0.45, p = 0.14) (Figure 4).
Discussion
The present study suggested a progressive return of CQ
susceptibility in four countries of West and Central Africa,
i.e., Senegal, Mali, Ivory Coast and Cameroon, based on
the surveillance of patients returning to non-endemic
areas with P. falciparum infection from 2000–2011. These
results, from both molecular and in vitro analyses, show
that CQ resistance was in decline during this period, ex-
cept in Mali. The same analyses performed for the period
2004–2011, after these countries had changed their na-
tional recommendations from CQ to alternative anti-
malarial drugs, confirm the increase of CQ susceptibility
and show an accentuated trend compared to the period
2000–2011, in Senegal, Ivory Coast and Cameroon. A sig-
nificant decrease of CQ resistance was observed in Mali
only after 2004.
The conclusions from these indirect measures of CQ
efficacy in travellers are consistent with similar measures
assessed in the field. For Senegal, the prevalence of
pfcrt76T isolates in travellers showed a similar trend asFigure 4 Evolution of the prevalence of pfcrt76 mutant isolates regar
observed (red crosses) and fitted (by logistic regression, red line) prevalenc
Senegal, Mali, Ivory Coast and Cameroon, from 2000 to 2011 (data from CN
and fitted (by logistic regression using linear mixed model, blue line) preva
fever in Senegal, Mali, Ivory Coast and Cameroon, from 2000 to 2011 (data
Cluster Survey).observed in two studies conducted in Dakar, but a differ-
ent trend from a study conducted in the city of Pikine,
located 15 km from Dakar [18,19,37]. These results are
also consistent with the East African countries, Malawi
and Kenya, where the return of CQ susceptibility was
observed following the official withdrawal of this drug.
Indeed, the prevalence of pfcrt76T mutant isolates in
travellers is comparable with previously published data
from the field in East Africa after the CQ ban and simi-
lar trends are described (Figure 2).
Although the trends are similar, there are variations
among the countries in the trends and many factors are
likely to explain these. Overall, the main factor is the ef-
ficiency with which new drug policies are implemented.
This is, in turn, strongly influenced by the political, eco-
nomic, geographic, social and cultural contexts within
each country and region. The pharmaceutical distribu-
tion modes and drug supply chains impact the use of
drugs, depending on the level of control that the gover
nMent exercises over the pharmaceutical distribution
system in the public and private sectors [38,39]. For ex-
ample, Malawi, which implemented successful national
information campaigns and efficient control of its dis-
tribution, was able to almost completely ban CQ use
and show, after 10 years, a complete recovery of the CQ
susceptibility [40]. In addition, overall malaria preva-
lence the distance between patients and public health
facilities, and socio-economic level, age of patients and
have also been identified as key factors for CQ useding the change in drug use, 2000–2011. The Y-axis represents the
e of pfcrt76 mutant isolates from travellers returning to France from
Rpalu, France). The Z-axis represents observed (blue upward triangle)
lence of CQ use among fever in children under five years-old with
from Demographic Health Survey and Multiple Indicator
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carrying parasites displaced from other regions is also a
potentially important factor. Deeper analysis in countries
that differ greatly in the response to withdrawal of a drug
will help to quantify the influence of these factors.
Despite the disparate influences, the overall effective-
ness of drug policy implementation has important and
far-reaching effects on the useful therapeutic life of anti-
malarial drugs by delaying the emergence of resistance.
Most important, following the emergence of resist-
ance, the time between official policy changes and their
subsequent implementation, directly impacts public
health; use of poorly effective drugs increases malaria
mortality and morbidity [10,11]. This consequence has
been confirmed in some studies which reported the de-
crease in the proportion of severe malaria cases and in
malaria-specific mortality after the introduction or dis-
tribution of free ACT [43-45].
The trends of CQ use, which were estimated using
DHS and MICS data, show a steady decrease for the
four countries of interest without major differences
among them. However, the slow decrease in the preva-
lence of the pfcrt76T allele observed in Mali might be
partly explained by the relatively slow decrease of CQ
consumption illustrated in Figure 4. The reversal from
high prevalence of the resistant mutant genotype
pfcrt76T within the parasite population to the wild type
genotype pfcrtK76 might be explained by the fitness cost
of the resistant mutant: there is evidence that the
parasites that carry the wild type pfcrt76K allele have a
survival advantage in the absence of drug pressure [40].
However, the positive correlation between CQ use and
prevalence of CQ resistance was only shown for Senegal
and Ivory Coast. Beyond country-specific drug policies
and efficacies in implementing them, other factors may
also play a role in differences between countries. For ex-
ample, transmission intensity, which differs between
sites, might impact the CQ use and therefore, the preva-
lence of mutant isolates. This is observed with reversion
back to the 76 K haplotype occurring during low trans-
mission seasons [46,47]. Multiple first-line therapies or
cycling strategies, where anti-malarial therapies are
rotated, might be one of the tools to decrease drug pres-
sure and help prevent the spread of resistance [48].
The four West and Central African countries currently
recommend the combination of artesunate-amodiaquine
as first-line treatment [49]. In addition to the recom-
mended first-line drugs, many other anti-malarials are
commonly used in these countries and selection
pressures on the pfcrt locus are complex. In Southeast
Asia, addition of artesunate to mefloquine was followed
by a partial reversal of mefloquine resistance [50,51].
Amodiaquine is closely related to CQ, and was also
used considerably in these four countries. The changefrom monotherapy with amodiaquine in combination
with artesunate may have provided reciprocal protection
to the artemisinin derivative and to the partner drug
influenced the return of amodiaquine and CQ suscep-
tibility. It is, therefore, possible that the significant de-
crease of IC50 for desethylamodiaquine might be
explained both by the decrease of CQ-resistant isolates
and the switch from amodiaquine monotherapy to
artesunate-amodiaquine combination therapy in West
and East African region after 2006. The decrease of
in vitro mefloquine susceptibility in Cameroon and Ivory
Coast may have selected CQ-susceptible isolates. Indeed,
the inverse correlation between CQ and mefloquine,
which was described in previous studies, could explain
the opposite trend [35,52].
The present study has several limitations worth noting.
Returning travellers are not a representative sample of
the native population and the precise location within the
country where infection occurred is not reported. How-
ever, trends for in vitro and molecular results for
imported malaria are similar to those observed in previ-
ous publications from Senegal [18,19]. For validation of
this approach, these results should be compared to
country-level in vitro and molecular data analysed in the
same conditions for the four countries. There are also
some limitations and bias regarding the consumption
data. The CQ use in children under five years old with
fever is used as a proxy of the CQ consumption in the
country. The data are only based on the mother’s declar-
ation and do not assess directly the blood drug concen-
tration. This approach is less reliable than biological
methods because of misunderstanding of questions,
failed memory or deliberate attempts to provide false in-
formation [53].
Emergence of resistance to artemisinin has also been
confirmed recently in different loci in Southeast Asia
[54,55]. This raises concerns about the potential spread
of this resistance in sub-Saharan Africa, as has been pre-
viously described for other anti-malarial drugs. Effective
surveillance systems to monitor anti-malarial drug resist-
ance in Africa are essential to protect the efficacy of
ACT. So, despite the limitations, surveillance of parasites
from travellers can be used to monitor the evolution of
resistance over time, and can provide useful information,
especially from areas where little information is avail-
able. Those data can be realised rapidly and methods
can be more easily standardized. This non-immune
population, unlikely to be re-infected, also facilitates de-
tection of resistant isolates and true clinical failure.
Conclusions
The longitudinal pattern of CQ resistance in four West
and Central African countries using travellers’ data was
described and the CQ withdrawal after policy change
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The length of time between policy changes and their
subsequent implementation, as well as the use of
analogue anti-malarial drugs, may affect the time for a
significant recovery of CQ sensitivity. Despite the regain
of CQ susceptibility, any reintroduction would likely to
result in a rapid re-emergence of resistance strains [56].
This study highlights the correlation between drug pres-
sure and resistance prevalence [57]. The rapidly evolving
pattern of anti-malarial drug resistance in endemic
countries emphasises the need for a sustainable surveil-
lance system, which would enable the implementation of
more longitudinal studies.
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